Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
Cryptococcal infections are responsible for significant morbidity and mortality in immunocompromised patients. Reports of these infections in patients on small molecular kinase inhibitors have not been widely reported in clinical trials. We describe one case of cryptococcal meningoencephalitis and o...
| Publicado en: | Journal of Oncology Pharmacy Practice Vol. 25; no. 3; pp. 710 - 715 |
|---|---|
| Autores principales: | , , |
| Formato: | case study tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
Apr2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135207531&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 135207531 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10781552 0JI jtl: Journal of Oncology Pharmacy Practice issn: 10781552 maglogo: Y pubinfo: dt: Apr2019 vid: 25 iid: 3 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 135207531 135207531 135207531 10.1177/1078155217752078 135207531 ppf: 710 ppct: 5 formats: tig: atl: Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia. aug: au: Stankowicz, Matthew Banaszynski, Megan Crawford, Russell affil: Southern Arizona VA Health Care System, Tucson, AZ, USA sug: subj: Immunocompromised Host Meningitis, Cryptococcal Etiology Cryptococcus Pneumonia Tyrosine Kinase Inhibitors Therapeutic Use Leukemia, Lymphocytic, Chronic Tyrosine Kinase Inhibitors Adverse Effects Atrial Fibrillation Aged Male Antigens Analysis Aged: 65+ years Male ab: Cryptococcal infections are responsible for significant morbidity and mortality in immunocompromised patients. Reports of these infections in patients on small molecular kinase inhibitors have not been widely reported in clinical trials. We describe one case of cryptococcal meningoencephalitis and one case of cryptococcal pneumonia in two patients who were receiving ibrutinib for chronic lymphocytic leukemia. Despite different sites of cryptococcal infection, both patients had similar presentations of acute illness. Patient 1 was worked up for health care–associated pneumonia, as well as acute sinusitis prior to the diagnosis of cryptococcal meningoencephalitis. He also had a more complex past medical history than patient 2. Patient 2 developed atrial fibrillation from ibrutinib prior to admission for presumed health care–associated pneumonia. Cryptococcal antigen testing was done sooner in this patient due to patient receiving high-dose steroids for the treatment of underlying hemolytic anemia. We conclude that patients who develop acute illness while receiving ibrutinib should be considered for cryptococcal antigen testing. pubtype: Academic Journal doctype: case study tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|